Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Protara Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 31
- −2 vs. Q2 2022
- Shares held
- 5.66M
- −269.2K (−4.5%) vs. Q2 2022
- Total value
- $16.7M
- −$1.67M (−9.1%) vs. Q2 2022
- New holders
- 2
- 3 more added
- Sold out
- 4
- 13 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 100 | $0 | 0.00% | 00.0% | Unchanged |
| American Portfolios Advisors | 100 | $296 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 244 | $1.00K | 0.00% | −2,210−90.1% | Reduced |
| UBS Group AG | 239 | $1.00K | 0.00% | −1,032−81.2% | Reduced |
| Wells Fargo & Company | 558 | $1.00K | 0.00% | −8−1.4% | Reduced |
| Federated Hermes, Inc. | 246 | $1.00K | 0.00% | −134−35.3% | Reduced |
| Acadian Asset Management LLC | 6,314 | $18.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 12,465 | $37.0K | 0.00% | +2,362+23.4% | Added |
| Dimensional Fund Advisors LP | 15,782 | $47.0K | 0.00% | −12,918−45.0% | Reduced |
| Bank of New York Mellon Corp | 17,907 | $53.0K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 18,864 | $56.0K | 0.00% | −6,802−26.5% | Reduced |
| Northern Trust Corp | 20,019 | $59.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 30,900 | $91.0K | 0.00% | 00.0% | Unchanged |
| Privium Fund Management (UK) Ltd | 35,000 | $104.0K | 0.13% | +35,000 | New |
| BlackRock Inc. | 35,501 | $105.0K | 0.00% | −3,007−7.8% | Reduced |
| Millennium Management LLC | 50,207 | $149.0K | 0.00% | −10,577−17.4% | Reduced |
| Two Sigma Investments, LP | 51,048 | $151.0K | 0.00% | −2,500−4.7% | Reduced |
| Two Sigma Advisers, LP | 52,418 | $155.0K | 0.00% | −700−1.3% | Reduced |
| Assenagon Asset Management S.A. | 58,389 | $173.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 64,000 | $189.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 79,200 | $234.0K | 0.00% | +25,000+46.1% | Added |
| Geode Capital Management, LLC | 83,644 | $247.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 170,522 | $505.0K | 0.00% | −72,049−29.7% | Reduced |
| Ikarian Capital, LLC | 188,664 | $558.0K | 0.28% | −69,189−26.8% | Reduced |
| Baker Bros. Advisors LP | 199,671 | $591.0K | 0.00% | 00.0% | Unchanged |
| Boxer Capital, LLC | 209,227 | $619.0K | 0.03% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 290,051 | $859.0K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 427,388 | $1.26M | 0.00% | −160.0% | Reduced |
| OrbiMed Advisors LLC | 830,641 | $2.46M | 0.05% | 00.0% | Unchanged |
| Opaleye Management Inc. | 2,708,067 | $7.99M | 3.30% | +23,900+0.9% | Added |
| Financial Advocates Investment Management | 1,161 | – | – | +1,161 | New |
| DLD Asset Management, LP | 0 | $0 | 0.00% | −157,349−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −15,969−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,807−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −352−100.0% | Sold out |